SCHEMBL147457

SCHEMBL147457

CN1CCC(NC(=O)C2CCc3c([nH]c4c(C(N)=O)cccc34)C2)CC1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.49
MAPK1 P28482 1/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
HSD17B10 Q99714 1/20 0.49
PARP1 P09874 7/20 0.41
BTK Q06187 7/20 0.41
ALDH1A1 P00352 1/20 0.39
GFER P55789 1/20 0.38
PARP2 Q9UGN5 2/20 0.38
DRD2 P14416 1/20 0.37
DRD1 P21728 1/20 0.37
DRD5 P21918 1/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
JAK3 P52333 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL151350 0.86 ALOX15 (0.51) ALOX15MAPK1CASP1CASP7HSD17B10
SCHEMBL19279346 0.77 ALOX15 (0.57) ALOX15MAPK1CASP1CASP7HSD17B10
SCHEMBL147737 0.74 ALOX15 (0.53) ALOX15MAPK1CASP1CASP7HSD17B10
SCHEMBL3690203 0.74 BTK (0.41) BTKJAK2JAK3
SCHEMBL3690201 0.73 BTK (0.42) BTKJAK2JAK3
SCHEMBL124375 0.73 BTK (0.41) BTKJAK2JAK3
SCHEMBL29564600 0.72 ALOX15 (0.58) ALOX15MAPK1CASP1CASP7HSD17B10
SCHEMBL29785261 0.72 ALOX15 (0.58) ALOX15MAPK1CASP1CASP7HSD17B10
SCHEMBL147456 0.69 ALDH1A1 (0.48) ALOX15MAPK1CASP1CASP7HSD17B10
SCHEMBL3702289 0.69 BTK (0.42) BTKJAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2391602-B1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-12-04 EP disclosed
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 ALOX15 4154/4885MAPK1 239/4885CASP1 701/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 ALOX15 4154/4885MAPK1 239/4885CASP1 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.